Emmaus Life Sciences (EMMA) AI Stock Analysis

Emmaus Life Sciences

(Other OTC:EMMA)

Select Model

Rating:42Neutral

Price Target:$0.03▼(-2.86% Downside)

Action:reiterated

Date:10/28/26

The overall score is heavily pressured by a critically weak balance sheet with negative equity and high leverage, posing a significant solvency risk. While recent operational cash flow has turned positive, the stock remains in a sustained downtrend across all major moving averages, and the company's unprofitability is reflected in a negative P/E ratio. The low share price adds further volatility risk.

Positive Factors

FDA-Approved Rare-Disease ProductAn FDA-approved therapy gives Emmaus an established commercial product and positions the company in a rare-disease market where specialized treatment needs can support durable demand. The sickle cell focus also provides a defined platform for related product and development efforts.

Negative Factors

Negative Equity and Debt BurdenPersistently negative equity and meaningful debt leave Emmaus with a thin financial cushion and limited balance-sheet flexibility. This structure can constrain investment capacity and increase refinancing or dilution risk, making the company more vulnerable if operating performance or cash generation weakens.

Emmaus Life Sciences (EMMA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $2.47M
Dividend Yield: ―
Average Volume (3M): 156.81K
Price to Earnings (P/E): -0.4
Beta (1Y): -1.44
Revenue Growth: 10.98%
EPS Growth: -72.08%
Country: US
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Emmaus Life Sciences Business Overview & Revenue Model

Company Description

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and...

How the Company Makes Money

Emmaus Life Sciences has historically generated revenue primarily from product sales of Endari (L-glutamine oral powder) for sickle cell disease. Revenue is generally recognized when product is sold and delivered to customers (e.g., wholesalers/speci...

Emmaus Life Sciences Financial Statement Overview

Summary

Operational improvements are evident with positive EBIT, strong gross margins, and positive free cash flow. However, the balance sheet is critically weak with negative equity and high leverage, posing severe solvency risks. The overall financial health is poor despite recent cash flow generation.

Income Statement

32Negative

Balance Sheet

12Very Negative

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Jun 2024	Dec 2022	Mar 2022
Income Statement
Total Revenue	15.53M	12.45M	16.65M	29.60M	18.39M	20.61M
Gross Profit	14.54M	11.60M	15.45M	28.25M	15.80M	17.30M
EBITDA	3.40M	-310.00K	-910.00K	3.62M	-5.50M	-12.76M
Net Income	-6.02M	-7.49M	-6.45M	-3.73M	-10.63M	-15.95M
Balance Sheet
Total Assets	16.37M	21.44M	23.60M	35.18M	48.23M	56.73M
Cash, Cash Equivalents and Short-Term Investments	2.81M	2.13M	1.39M	2.55M	2.02M	2.28M
Total Debt	30.52M	32.56M	32.96M	32.65M	30.82M	29.91M
Total Liabilities	82.55M	85.04M	80.08M	82.94M	82.32M	78.18M
Stockholders Equity	-66.18M	-63.61M	-56.48M	-47.76M	-34.09M	-21.45M
Cash Flow
Free Cash Flow	3.96M	-12.00K	-2.30M	-1.52M	-5.10M	-1.33M
Operating Cash Flow	3.97M	-11.00K	-2.29M	-1.50M	-5.07M	-1.25M
Investing Cash Flow	1.58M	2.17M	2.50M	-432.00K	-2.39M	-6.38M
Financing Cash Flow	-3.60M	-1.43M	-1.35M	2.48M	7.23M	7.41M

Emmaus Life Sciences Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.04

Price Trends

50DMA0.06Negative

100DMA0.03Positive

200DMA0.02Positive

Market Momentum

MACD-0.00Positive

RSI40.13Neutral

STOCH24.60Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.13 is Neutral, neither overbought nor oversold. The STOCH value of 24.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EMMA.

Emmaus Life Sciences Risk Analysis

Emmaus Life Sciences disclosed 32 risk factors in its most recent earnings report. Emmaus Life Sciences reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Emmaus Life Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

EMMA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	42Neutral	$3.84M	-0.18	-166.67%	―	―	88.77%
EMMA	42Neutral	$2.47M	-0.37	9.37%	―	10.98%	-72.08%
SCNI	41Neutral	$268.82K	0.00	-26.63%	―	30.12%	-165.46%

* Healthcare Sector Average

Performance Comparison

EMMA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
EMMA	Emmaus Life Sciences Inc	0.04	0.02	218.18%
SCNI	Scinai Immunotherapeutics Ltd. Sponsored Adr	0.47	-10.83	-95.83%
ADTX	Aditxt, Inc.	0.04	-1123.16	-100.00%
DRMA	Dermata Therapeutics, Inc.	0.78	-2.29	-74.76%
CERO	Cero Therapeutics Holdings, Inc.	0.01	-0.09	-90.00%
CDT	Cdt Equity Inc.	0.07	-15249.93	-100.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Emmaus Life Sciences AI Stock Analysis